RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

OANDA Prop Trader vs Upcomers

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

OAPT

OANDA Prop Trader

UPCM

Upcomers

EST. 2023

OANDA PROP TRADER

METRIC

UPCOMERS

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

—

MAX FUNDING

—

MIN COST

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

OANDA PROP TRADER DETAILS

STEPS: -phase

UPCOMERS DETAILS

STEPS: -phase

OANDA Prop Trader PROS

+OANDA is a well-known brand name, though no specific firm data is provided
+No fee, payout, or structure data is available to identify above-average metrics
+No platform or market data is available to assess trading flexibility
+No founding date or structural data is available for comparison

OANDA Prop Trader CONS

−No data is provided for this firm, making any meaningful comparison impossible
−Traders cannot assess profit split, funding, or costs against industry averages
−Complete absence of data is a significant transparency concern for traders making financial decisions

Upcomers PROS

+Czech Republic is an EU-member jurisdiction, which may offer relevant regulatory context for European traders.
+No further data is available to substantiate additional pros at this time.
+No platform or market data is provided to assess trading conditions.
+No funding or cost data is available to compare against industry benchmarks.

Upcomers CONS

−Founded in 2023, making Upcomers a very new firm with minimal operational track record.
−No profit split, drawdown, funding, or challenge cost data is available for industry comparison.
−Lack of transparency around key metrics makes it very difficult for traders to make informed decisions.

PROPDNA VERDICT